Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CAR-NK+ T cell therapeutics - CRISPR Therapeutics/Nkarta Therapeutics

Next Previous
Search
Drug Profile

CAR-NK+ T cell therapeutics - CRISPR Therapeutics/Nkarta Therapeutics

Alternative Names: Chimeric antigen receptor NK+T cell therapeutics-CRISPR Therapeutics/Nkarta Therapeutics; NK+T cell therapeutics-CRISPR Therapeutics/Nkarta Therapeutics

Latest Information Update: 02 Jun 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CRISPR Therapeutics; Nkarta Therapeutics
  • Class Antineoplastics; CAR-NK cell therapies; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 07 May 2021 CRISPR Therapeutics and Nkarta Therapeutics agree to co-develop and co-promote CRISPR/Cas9 gene-edited cell therapies for Cancer
  • 07 May 2021 Early research in Cancer in USA (Parenteral), prior to May 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top